Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuhiro Tanaka

Showing results (31-40 of 148) with videos related to

Pageof 15
Sort By:
Nephron|December 14, 2016
Effect of AST-120 in Chronic Kidney Disease Treatment: Still a Controversy?Junna Yamaguchi, Tetsuhiro Tanaka, Reiko Inagi
Seminars in Nephrology|September 10, 2013
Novel therapeutic strategy with hypoxia-inducible factors via reversible epigenetic regulation mechanisms in progressive tubulointerstitial fibrosisImari Mimura, Tetsuhiro Tanaka, Masaomi Nangaku
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|June 10, 2021
[Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor]Sayako Maruno, Tetsuhiro Tanaka, Masaomi Nangaku
Expert Opinion on Pharmacotherapy|June 19, 2024
Evaluating the safety and efficacy of vadadustat for the treatment of anemia associated with chronic kidney diseaseImari Mimura, Tetsuhiro Tanaka, Masaomi Nangaku
Biomedicines|February 26, 2025
The Many Faces of Protease-Activated Receptor 2 in Kidney InjuryYuji Oe, Tetsuhiro Tanaka, Nobuyuki Takahashi
Expert Opinion on Pharmacotherapy|October 23, 2021
An evaluation of roxadustat for the treatment of anemia associated with chronic kidney diseaseYu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku
Current Opinion in Nephrology and Hypertension|May 27, 2020
Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney diseaseYu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku
Current Opinion in Nephrology and Hypertension|October 9, 2019
Nuclear factor erythroid 2-related factor 2 as a treatment target of kidney diseasesMarie Ito, Tetsuhiro Tanaka, Masaomi Nangaku
Kidney Research and Clinical Practice|March 31, 2022
Exploring molecular targets in diabetic kidney diseaseSayako Maruno, Tetsuhiro Tanaka, Masaomi Nangaku
Kidney International|June 28, 2017
Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney diseaseMai Sugahara, Tetsuhiro Tanaka, Masaomi Nangaku
Pageof 15

Showing results (31-40 of 148) with videos related to

Sort By:
Pageof 15
Nephron|December 14, 2016
Effect of AST-120 in Chronic Kidney Disease Treatment: Still a Controversy?Junna Yamaguchi, Tetsuhiro Tanaka, Reiko Inagi
Seminars in Nephrology|September 10, 2013
Novel therapeutic strategy with hypoxia-inducible factors via reversible epigenetic regulation mechanisms in progressive tubulointerstitial fibrosisImari Mimura, Tetsuhiro Tanaka, Masaomi Nangaku
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|June 10, 2021
[Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor]Sayako Maruno, Tetsuhiro Tanaka, Masaomi Nangaku
Expert Opinion on Pharmacotherapy|June 19, 2024
Evaluating the safety and efficacy of vadadustat for the treatment of anemia associated with chronic kidney diseaseImari Mimura, Tetsuhiro Tanaka, Masaomi Nangaku
Biomedicines|February 26, 2025
The Many Faces of Protease-Activated Receptor 2 in Kidney InjuryYuji Oe, Tetsuhiro Tanaka, Nobuyuki Takahashi
Expert Opinion on Pharmacotherapy|October 23, 2021
An evaluation of roxadustat for the treatment of anemia associated with chronic kidney diseaseYu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku
Current Opinion in Nephrology and Hypertension|May 27, 2020
Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney diseaseYu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku
Current Opinion in Nephrology and Hypertension|October 9, 2019
Nuclear factor erythroid 2-related factor 2 as a treatment target of kidney diseasesMarie Ito, Tetsuhiro Tanaka, Masaomi Nangaku
Kidney Research and Clinical Practice|March 31, 2022
Exploring molecular targets in diabetic kidney diseaseSayako Maruno, Tetsuhiro Tanaka, Masaomi Nangaku
Kidney International|June 28, 2017
Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney diseaseMai Sugahara, Tetsuhiro Tanaka, Masaomi Nangaku
Pageof 15